Serum collection after Gamma-PN vaccination to support assay development

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Twelve participants will receive a single dose of Gamma-PN and have serum collected before dosing and again on Day 28 to provide samples for assay development and validation. The open-label, Phase 1 interventional protocol is limited to one site at the University of Adelaide Clinical Research Facility. Eligible volunteers must be in good general health and not have previously received a pneumococcal vaccine. Samples will be used to optimize and validate laboratory methods rather than to measure therapeutic outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* good general health

Exclusion Criteria:

* no previous pneumococcal vaccine

Where it's running

• University of Adelaide Clinical Research Facility
  Adelaide, South Australia, Australia Recruiting

Study contacts

• Study coordinator: Nerissa Lakhan, PhD
• Email: nerissa@gpnvaccines.com
• Phone: +61-432 161 783

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Safety and immune response of three PG4 vaccine lots vs 20vPnC in adults

  This study tests three different lots of a new pneumococcal vaccine and the standard 20vPnC vaccine in adults to see if they are similarly safe and provoke a similar immune response.

  Recruiting at 37 sites Phase 3 Pfizer · Birmingham, Alabama and 36 other locations · NCT07794748

• New pneumococcal vaccine safety and immune response in children and teens

  This study tests whether a new pneumococcal vaccine is as safe and as effective as Prevnar 20 in children and adolescents who have previously received PCV.

  Recruiting at 68 sites Phase 3 Pfizer · Birmingham, Alabama and 76 other locations · NCT07660198

• New pneumococcal vaccine in infants shows safety and how it stacks up against Prevnar 20

  A new pneumococcal vaccine is being tested in healthy infants to see if it is as safe as Prevnar 20 and whether it triggers a similar or better immune response.

  Recruiting at 125 sites Phase 3 Pfizer · Bessemer, Alabama and 129 other locations · NCT07629440

• New pneumococcal vaccine for healthy infants

  A new pneumococcal vaccine is being tested in about 2-month-old healthy babies to see if it is as safe as Prevnar 20 and whether it may offer broader protection against germs that cause pneumonia, meningitis, and ear infections.

  Recruiting at 72 sites Phase 3 Pfizer · Estero, Florida and 90 other locations · NCT07573462

• How pneumococcal conjugate vaccines may produce antibodies that protect against serogroup 33.

  This will try two different pneumococcal conjugate vaccines in healthy adults to see which one makes antibodies that can kill serogroup 33 bacteria.

  Recruiting Phase 4 University of Alabama at Birmingham · Birmingham, Alabama · NCT07135453

• Pneumococcal Vaccine Test for severely malnourished kids in hospital

  This study tests whether giving Pneumosil to children aged 6–59 months with severe acute malnutrition in hospital elicits a better immune response than a Typhoid vaccine, with follow-up visits over six months.

  Recruiting Phase 4 Menzies School of Health Research · Dili · NCT06817421

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.